

Fig S12: ISR induced by pitavastatin is due to PERK in L363, but other kinases may play a role in different MMCLs. PERK knockout (KO) was achieved in two clones of L363 A. Knockout was confirmed blotting for PERK and by 16-hour treatment with tunicamycin. KO clones had reduced phosphorylated eIF2 $\alpha$  and were not able to upregulate ATF4 in response to tunicamycin 5 µg/mL.

**B.** Cells were treated with pitavastatin 1  $\mu$ M for 40hrs to induce ATF4 upregulation. PERK knockout blocked ATF4 increases in the two knockout clones.

**C.** ISRIB can no longer rescue from the pitavastatin-mediated venetoclax sensitization in a 40hr Annexin V-PI assay of the PERK-KO clone 2. Mean +/- SD, n=2.

D. An effective concentration of the PERK inhibitor AMG-PERK44 was selected by dose titration under 5 μg/mL Tunicamycin to activate PERK in L363, OPM2, NCIH929, and MM1S.
3 μM AMG-PERK44 was sufficient to block tunicamycin-mediated ATF4 induction in L363, OPM2, and NCIH929.